{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Class (Stereo):
CHEMICAL (ACHIRAL)
Guanoxyfen sulfate is an antidepressant, antihypertensive. Guanoxyfen sulfate is an inhibitor of vasoconstrictor responses to sympathetic nerve stimulation. It could potentiate the actions of adrenaline and noradrenaline. It also could increase the blood glucose concentration and decrease the appetite.
Class (Stereo):
CHEMICAL (RACEMIC)
Eliprodil, also known as SL 82-0715, is a non-competitive NMDA glutamate receptor antagonist, which targets the polyamine modulatory site and is selective for NR2B subunit-containing receptors. Eliprodil was in phase III clinical trial for the treatment of stroke or traumatic brain injury. However, these investigations were failed. One reason suggested for failure was that eliprodil had blocked the synaptic transmission mediated by NMDA receptors, hindering neuronal survival. In addition, eliprodil has been studied in phase II clinical trials for the treatment of Parkinson's disease.
Class (Stereo):
CHEMICAL (ACHIRAL)
Carbophenothion is a highly toxic organophosphate insecticide used as a citrus pesticide called Trithion. Carbophenothion is a potent inhibitor of acetylcholinesterase, a neuromuscular enzyme that is widely needed for the normal function of insects, as well as people and many other animals. The Environmental Protection Agency (EPA) classifies it as a Restricted Pesticide (RUP). Carbophenothion is used in various brands, such as Trithion. This pesticide contains 80% Carbophenothion as its only active ingredient. Due to the widespread use of these organophosphates in the United States in the nineties, this was the most common cause of agricultural poisoning. Carbophenothion is used as an insecticide and acaricide, the main purpose of which is to protect citrus fruits, but also to protect the cotton from aphids (lice) and spider mites. In addition, it is used in combination with oil, and also as a pesticide against many other pests on fruits, nuts, vegetables, sorghum, corn, and others. In addition, it is used to combat animal parasites.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Alvameline is a partial agonist of the M1 mAChR that also displays M2/M3 antagonist effects. It readily crosses the blood-brain barrier. It has an effect profile that makes it of interest to test its ability to counteract bladder overactivity in humans. Behaviorally, alvameline has been shown to significantly improve Morris water maze (MWM) performance in both young and ageimpaired rats. It failed to improve cognition in patients with mild to moderate Alzheimer's disease.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ritanserin (INN, USAN, BAN) is a serotonin receptor antagonist which was never marketed for clinical use but has been used in scientific research. In humans, ritanserin increases deep slow-wave sleep, improved liveliness in a variety of psychiatric disorders and facilitated participation in behaviour therapy. During clinical trials, unexpected observations indicated that ritanserin may be of value in treating obsessive-compulsive disorder, acute mania, negative symptoms of schizophrenia, drug addicts, etc. Clinical observations confirmed the efficacy of ritanserin in the chronic withdrawal phase after detoxification from ethanol. Ritanserin had been in phase III clinical trials by Janssen L.P. for the treatment of anxiety disorder and major depressive disorder. However, the clinical development of ritanserin was discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. It was studied in experimental osteoarthritis, in patients with mild active systemic lupus erythematosus and in systemic sclerosis patients. In January 2014, the US FDA granted orphan drug designation to paquinimod for the treatment of systemic scleroderma. The Orphan designation is implemented to promote the development of drugs that may provide significant benefit to patients suffering from rare diseases identified as life threatening or chronically debilitating. The further development of paquinimod for systemic lupus erythematosus and rheumatoid arthritis was discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Amenamevir is an antiviral agent discovered by Astellas Pharma Inc. and is considered to exert anantiviral effect by inhibiting the activity of the helicase-primase complex, which is involved in DNA replication of herpes virus. It is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster virus. Amenamevir inhibited the in vitro replication of HSV-1 with a mean 50% effective concentration (EC(50)) of 14 ng/ml. Amenamevir was approved in Japan for the treatment of Herpes zoster.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Procymate is a cyclohexylpropyl derivative patented by Compagnie Francaise des Matieres Colorantes as a non-hypnogenic depressor of the nervous system.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Fantridone is an antidepressant.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Amelubant, its metabolite BIIL 260 (formed by removal of the ethoxycarbonyl protecting group), and its major metabolite BIIL 315 (formed by removal of the protecting group and glucuronidation) had potent in vitro and in vivo Leukotriene B4 receptor antagonistic properties. Amelubant has been in phase II clinical trials by Boehringer Ingelheim for the treatment of cystic fibrosis, chronic obstructive pulmonay disease, bronchial asthma and rheumatoid arthritis. However, this research has been discontinued. In 2002, orphan drug designation was received in E.U. for the treatment of cystic fibrosis. Serious adverse events of Amelubant were characterized by increased presentation of respiratory signs and/or symptoms associated with pulmonary exacerbation and resulted in admission to a hospital and/or administration of IV antibiotics.